Diamond Hill Capital Management Inc. Lowers Holdings in Enovis Co. (NYSE:ENOV)

Diamond Hill Capital Management Inc. lessened its position in shares of Enovis Co. (NYSE:ENOV - Free Report) by 7.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,791,436 shares of the company's stock after selling 213,258 shares during the quarter. Diamond Hill Capital Management Inc. owned about 4.91% of Enovis worth $122,488,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of ENOV. Confluence Investment Management LLC acquired a new position in Enovis during the 4th quarter valued at approximately $3,494,000. Geode Capital Management LLC boosted its holdings in shares of Enovis by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 921,437 shares of the company's stock valued at $39,678,000 after acquiring an additional 80,165 shares during the last quarter. UMB Bank n.a. boosted its holdings in shares of Enovis by 128.2% in the 4th quarter. UMB Bank n.a. now owns 778 shares of the company's stock valued at $34,000 after acquiring an additional 437 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Enovis in the 3rd quarter valued at $1,050,000. Finally, Jane Street Group LLC boosted its holdings in shares of Enovis by 247.6% in the 3rd quarter. Jane Street Group LLC now owns 106,684 shares of the company's stock valued at $4,593,000 after acquiring an additional 75,988 shares during the last quarter. Institutional investors own 98.45% of the company's stock.

Enovis Price Performance

Shares of NYSE ENOV traded down $0.20 during mid-day trading on Tuesday, reaching $38.99. The company's stock had a trading volume of 1,032,887 shares, compared to its average volume of 663,984. The stock has a 50-day moving average of $43.21 and a two-hundred day moving average of $43.67. The stock has a market capitalization of $2.22 billion, a P/E ratio of -17.80 and a beta of 2.05. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. Enovis Co. has a 1-year low of $35.14 and a 1-year high of $62.79.

Remove Ads

Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.06. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The firm had revenue of $560.98 million during the quarter, compared to analysts' expectations of $555.14 million. On average, equities research analysts anticipate that Enovis Co. will post 2.79 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Needham & Company LLC lowered their price target on shares of Enovis from $65.00 to $64.00 and set a "buy" rating on the stock in a report on Thursday, February 27th.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.